Adnan M. Dahdul, M.D.

CLOSEOUT LETTER Adnan M. Dahdul, M.D. MARCS-CMS 719607 — May 15, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Product: Biologics Recipient: Recipient Name Adnan Dahdul, MD Adnan M. Dahdul, M.D. 95 Frank B Murray Street Springfield , MA 01103 United States adahdul@sisuhealth.com Issuing Office: Office of Compliance and Biologics Quality United States Secondary Issuing Offices United States Dear Dr. Dahdul: The Food and Drug Administration (FDA) has completed an evaluation of your corrective actions in response to our Warning Letter CBER-26-719607 dated March 11, 2026. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you from your responsibility to take all necessary steps to ensure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations. The Agency expects you to continuously comply with the law and will monitor your state of compliance. Sincerely, /S/ Carrie M. Mampilly, MPH Director, Division of Inspections and Surveillance Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research CC: Mishelle Harriger, SCSO, OII, OBMI Division 1 OIIBIMODivision1Correspondence@fda.hhs.gov Content current as of: 05/28/2026 Regulated Product(s) Biologics